Form 4: Vertex Pharma CLO Gains Shares from PSU Vesting

Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals, acquired 9,068 shares of common stock through the vesting of performance stock unit awards.

Summary

• Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), acquired a total of 9,068 shares of common stock.
• These shares were acquired through the vesting of two performance stock unit (PSU) awards.
• The first award, granted on February 1, 2023, resulted in 6,294 shares.
• The second award, granted on February 12, 2025, resulted in 2,774 shares.
• The company's management development and compensation committee certified the attainment of performance goals for both awards on January 22, 2026.
• The 6,294 shares are scheduled to vest on February 13, 2026.
• The 2,774 shares are scheduled to vest in installments beginning on February 24, 2026.
• Following these transactions, Jonathan Biller's direct beneficial ownership of Vertex Pharmaceuticals common stock totals 24,374 shares.

Sentiment

Score: 7

Explanation: The filing indicates the successful achievement of performance goals leading to the vesting of executive equity awards, which is a positive sign for company performance and executive alignment with shareholder interests.

Positives

• Indicates successful attainment of performance goals by the company, leading to the vesting of executive compensation.
• Increases the alignment of executive interests with shareholder value through increased equity ownership.

Future Outlook

Future vesting of performance shares for the EVP and Chief Legal Officer is scheduled for February 2026, reflecting previously set compensation milestones.

Industry Context

This transaction represents a standard practice for executive equity compensation within the pharmaceutical and biotechnology industries, aligning executive incentives with company performance.

Comparison to Industry Standards

• This transaction represents a standard practice for executive equity compensation within the pharmaceutical and biotechnology industries, aligning executive incentives with company performance.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value.
• Employees: Reflects a functioning performance-based compensation system.

Next Steps

• Vesting of 6,294 shares on February 13, 2026.
• Vesting of 2,774 shares in installments beginning February 24, 2026.

Key Dates

Recommendation

This Form 4 reports the routine vesting of performance-based equity awards for an executive. While it indicates successful performance goal attainment, it does not provide new fundamental information to warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, SEC filing, insider transaction, stock award, performance shares, executive compensation, Jonathan Biller